International PCNSL Collaborative Group Consensus Guidelines for the Assessment of Response in PCNSL7
Response . | Brain imaging . | Steroid dose . | Ophthalmologic examination . | CSF cytology . |
---|---|---|---|---|
Complete response | No contrast enhancing disease | None | Normal | Negative |
Unconfirmed complete response | No contrast enhancing disease | Any | Normal | Negative |
Minimal enhancing disease | Any | Minor RPE abnormality | Negative | |
Partial response | 50% decrease in enhancement | NA | Normal or minor RPE abnormality | Negative |
No contrast-enhancing disease | NA | Decrease in vitreous cells or retinal infiltrate | Persistent or suspicious | |
Progressive disease | 25% increase in enhancing disease | NA | Recurrent or new disease | Recurrent or positive |
Any new site of disease | ||||
Stable disease | All scenarios not covered by responses above |
Response . | Brain imaging . | Steroid dose . | Ophthalmologic examination . | CSF cytology . |
---|---|---|---|---|
Complete response | No contrast enhancing disease | None | Normal | Negative |
Unconfirmed complete response | No contrast enhancing disease | Any | Normal | Negative |
Minimal enhancing disease | Any | Minor RPE abnormality | Negative | |
Partial response | 50% decrease in enhancement | NA | Normal or minor RPE abnormality | Negative |
No contrast-enhancing disease | NA | Decrease in vitreous cells or retinal infiltrate | Persistent or suspicious | |
Progressive disease | 25% increase in enhancing disease | NA | Recurrent or new disease | Recurrent or positive |
Any new site of disease | ||||
Stable disease | All scenarios not covered by responses above |